Favipiravir

Generic Name: Favipiravir

Drug Type: Small Molecule

Chemical Formula: C_₅H_₄FN_₃O_₂

CAS Number: 259793-96-9

Unique Ingredient Identifier: EW5GL2X7E0

Background: Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.

Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.

Indication: ⑴用于埃博拉病毒感染的治疗。

⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）

Associated Conditions: Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza

Clinical Trials

Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy

Phase 1

Conditions: Covid19
Sars-CoV-2 Infection
ARDS, Human
Severe covid19

Interventions: Drug: Avigan
Combination Product: autologous activated platelet-rich plasma

First Posted Date: 2021-01-20

Last Posted Date: 2021-01-20

Lead Sponsor: Hayandra Peduli Foundation

Target Recruit Count: 30

Registration Number: NCT04715360

Locations: 🇮🇩
Koja Regional Public Hospital, Jakarta, DKI Jakarta, Indonesia

Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal

Phase 3

Conditions: Covid19

Interventions: Drug: Favipiravir
Drug: Placebo
Drug: Remdesivir

First Posted Date: 2021-01-05

Last Posted Date: 2021-01-05

Lead Sponsor: Nepal Health Research Council

Target Recruit Count: 676

Registration Number: NCT04694612

Locations: 🇳🇵
Charak Memorial Hospital, Pokhara, Gandaki, Nepal
🇳🇵
Armed Police Force Hospital, Kathmandu, Bagmati, Nepal

Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions

Phase 1

Conditions: Bioequivalence

Interventions: Drug: AVICOD 200 MG Film Tablet
Drug: AVIGAN 200 MG Film Tablets

First Posted Date: 2020-12-03

Last Posted Date: 2020-12-03

Lead Sponsor: Pharma Plant

Target Recruit Count: 30

Registration Number: NCT04651959

Locations: 🇹🇷
Novagenix Drug R&D Center, Akyurt, Ankara, Turkey

Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia

Phase 3

Completed

Conditions: Covid19
Infectious Disease
SARS-CoV Infection

Interventions: Drug: Favipiravir
Drug: Azithromycin

First Posted Date: 2020-11-03

Last Posted Date: 2023-03-08

Lead Sponsor: Ina-Respond

Target Recruit Count: 130

Registration Number: NCT04613271

Locations: 🇮🇩
RSPI Sulianti Saroso, Jakarta, DKI Jakarta, Indonesia
🇮🇩
RSJ Soerodjo, Magelang, Central Java, Indonesia
🇮🇩
RSUP Dr. Kariadi, Semarang, Central Of Java, Indonesia

The Prevent Severe COVID-19 (PRESECO) Study

Phase 3

Completed

Conditions: Covid19

Interventions: Drug: Favipiravir
Drug: Placebo

First Posted Date: 2020-10-23

Last Posted Date: 2024-03-29

Lead Sponsor: Appili Therapeutics Inc.

Target Recruit Count: 1187

Registration Number: NCT04600895

Locations: 🇺🇸
Quality Professional HealthCare, Miami, Florida, United States
🇺🇸
Continental Clinical Research, LLC, Miami, Florida, United States
🇺🇸
Sanitas Research, LLC, Miami, Florida, United States

and more 34 locations

Clinical Trial of Favipiravir Treatment of Patients With COVID-19

Phase 3

Completed

Conditions: SARS-CoV-2 Infection

Interventions: Drug: Favipiravir

First Posted Date: 2020-10-23

Last Posted Date: 2022-11-01

Lead Sponsor: University of Pecs

Target Recruit Count: 14

Registration Number: NCT04600999

Locations: 🇭🇺
First Department of Internal Medicine, University of Szeged, Szeged, Hungary
🇭🇺
National Korányi Institute for Pulmonology, Budapest, Hungary
🇭🇺
Institute of Infectology, University of Debrecen, Debrecen, Hungary

and more 2 locations

The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19

Phase 3

Conditions: Covid19

Interventions: Drug: Favipiravir
Drug: Oseltamivir 75mg

First Posted Date: 2020-09-22

Last Posted Date: 2020-09-22

Lead Sponsor: Indonesia University

Target Recruit Count: 100

Registration Number: NCT04558463

Locations: 🇮🇩
Cipto Mangunkusumo National Referral Hospital, Jakarta, DKI Jakarta, Indonesia

Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Standard of care
Drug: Favipiravir

First Posted Date: 2020-09-09

Last Posted Date: 2020-11-05

Lead Sponsor: Promomed, LLC

Target Recruit Count: 200

Registration Number: NCT04542694

Locations: 🇷🇺
City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation
🇷🇺
Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation
🇷🇺
Smolensk clinical hospital №1, Smolensk, Russian Federation

and more 2 locations

COVID-19 Treatment in South Africa

Phase 2

Completed

Conditions: COVID-19

Interventions: Other: Standard of care (Paracetamol)
Drug: Artesunate-amodiaquine
Drug: Pyronaridine-artesunate
Drug: Favipiravir plus Nitazoxanide
Drug: Sofosbuvir/daclatasvir